

DAFTAR PUSTAKA

- Abdulla, N.A., Balata, G.F., El-ghamry, H.A., dan Gomaa, E. 2021. Intranasal Delivery of Clozapine Using Nanoemulsion-based In-situ Gels: An Approach for Bioavailability Enhancement. *Saudi Pharmaceutical Journal*. 29(1), 1566-1485.
- Alaayedi, M.H. and Maraie, N.K., 2023. Lomustine's nanoemulsion as nose-to brain drug delivery system for CNS tumor treatment. *Saudi Pharmaceutical Journal*. 31(8), 101692.
- Bayanati, M., Khosroshahi, A.G., Alvandi, M. and Mahboobian, M.M., 2021. Fabrication of a thermosensitive in situ gel nanoemulsion for nose to brain delivery of temozolomide. *Journal of Nanomaterials*. 2021, 1-11.
- Bonferoni, M.C., Rossi, S., Sandri, G., Ferrari, F., Gavini, E., Rassa, G. and Giunchedi, P., 2019. Nanoemulsions for "nose-to-brain" drug delivery. *Pharmaceutics*. 11(2), 84.
- Chen, B., dan Inbaraj, B.S. 2019. Nanoemulsi and Nanoliposome Based Strategies for Improving Anthocyanin Stability. *Nutrients*, 11: 1-21.
- Huang, C., Wang, C., Zhang, W., Yang, T., Xia, M., Lei, X., Peng, Y., Wu, Y., Feng, J., Li, D. and Zhang, G., 2022. Preparation, In Vitro and In Vivo Evaluation of Nanoemulsion In Situ Gel for Transnasal Delivery of Traditional Chinese Medicine Volatile Oil from *Ligusticum sinense Oliv. cv. Chaxiong*. *Molecules*. 27(21), 7644.
- Lee, D. and Minko, T., 2021. Nanotherapeutics for nose-to-brain drug delivery: an approach to bypass the blood brain barrier. *Pharmaceutics*. 13(12), 2049.
- Jarvis, J.N., Lawrence, D.S., Meya, D.B., Kagimu, E., Kasibante, J., Mpoza, E., Rutakingirwa, M.K., Ssebambulidde, K., Tugume, L., Rhein, J. and Boulware, D.R., 2022. Single-dose liposomal amphotericin B treatment for cryptococcal meningitis. *New England Journal of Medicine*. 386(12), 1109-1120.
- Jang, J.H., Jeong, S.H. and Lee, Y.B., 2020. Enhanced lymphatic delivery of methotrexate using W/O/W nanoemulsion: in vitro characterization and pharmacokinetic study. *Pharmaceutics*. 12(10), 978.
- Kotta, S., Aldawsari, H.M., Badr-Eldin, S.M., Nair, A.B., Kaleem, M. and Dalhat, M.H., 2022. Thermosensitive hydrogels loaded with resveratrol nanoemulsion: Formulation optimization by central composite design and evaluation in MCF-7 human breast cancer cell lines. *Gels*. 8(7), 450.
- Marzaman, A.N.F., Mudjahid, M., Roska, T.P., Sam, A. and Permana, A.D., 2022. Development of chloramphenicol whey protein-based microparticles incorporated into thermoresponsive in situ hydrogels for


improved wound healing treatment. *International Journal of Pharmaceutics*. 628, 122323.

- Michels, L.R., Fachel, F.N.S., Schuh, R.S., Azambuja, J.H., de Souza, P.O., Gelsleichter, N.E., et al., 2023. Nasal administration of a temozolomide loaded thermoresponsive nanoemulsion reduces tumor growth in a preclinical glioblastoma model. *Journal of Controlled Release*. 355, 343-357. doi: 10.1016/j.jconrel.2023.01.070.
- Mudjahid, M., Asri, R.M., Nainu, F. and Permana, A.D., 2023. Validation of spectrophotometric method to quantify chloramphenicol in fluid and rat skin tissue mimicking infection environment: Application to in vitro release and ex vivo dermatokinetic studies from dissolving microneedle loaded microparticle sensitive bacteria. *Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy*, 291.122374. doi: 10.1016/j.saa.2023. 122374.
- Nemade, S.M., Kakad, S.P., Kshirsagar, S.J. and Padole, T.R., 2022. Development of nanoemulsion of antiviral drug for brain targeting in the treatment of neuro-AIDS. *Beni-Suef University Journal of Basic and Applied Sciences*. 11(1), 138.
- Permana, A.D., Utami, R.N., Courtenay, A.J., Manggau, M.A., Donnelly, R.F. & Rahman, L. 2020. Phytosomal nanocarriers as platforms for improved delivery of natural antioxidant and photoprotective compounds in propolis: An approach for enhanced both dissolution behaviour in biorelevant media and skin retention profiles. *Journal of Photochemistry and Photobiology B: Biology*, 205(February): 111846. <https://doi.org/10.1016/j.jphotobiol.2020.111846>.
- Petraitis, V., Petraitiene, R., Jessica, M., Valdez, Pyrgos, V., Lizak, M.J., et al., 2019. Amphotericin B Penetrates into the Central Nervous System through Focal Disruption of the Blood-Brain Barrier in Experimental Hematogenous *Candida Meningoencephalitis*. *American Society for Microbiology*. 63(12), 1-32.
- Rajasingham, R., Govender, N.P., Jordan, A., Loyse, A., Shroufi, A., Denning, D.W., Meya, D.B., Chiller, T.M. and Boulware, D.R., 2022. The global burden of HIV-associated cryptococcal infection in adults in 2020: a modelling analysis. *The Lancet Infectious Diseases*. 22(12), 1748-1755.
- Rehman, Q., Akash, M.S.H., Rasool, M.F. and Rehman, K., 2020. Role of kinetic models in drug stability. *Drug Stability and Chemical Kinetics*. 155-165.
- Rios, A., Batain, F., Barros., C., Paula, D., Martins, M., Chaud, M., dan Alves, T. 2021. Development and Validation of a Fast and Selective HPLC Method for the Determination of Amphotericin B in Nose-to-Brain Nanoliposome. *Letters in Applied NanoBioScience*. 10(2), 2309-2319.


- Ueta, I., 2022. Gas chromatographic determination of volatile compounds. *Analytical Sciences*. 38(5), 737-738.
- Verekar, R.R., Gurav, S.S. and Bolmal, U., 2020. Thermosensitive mucoadhesive in situ gel for intranasal delivery of Almotriptan malate: Formulation, characterization, and evaluation. *Journal of Drug Delivery Science and Technology*. 58, 101778.
- Wang, J., Ma, Y., Hou, S., Miao, Z. and Ma, Q., 2020. Interaction of amphotericin B and saturated or unsaturated phospholipid monolayers containing cholesterol or ergosterol at the air-water interface. *Biophysical Chemistry*. 258, 106317.
- Zhou, F., Oad, A., Zhu, H. and Li, C., 2021. Quantitative Analysis of Polymetallic Ions in Industrial Wastewater Based on Ultraviolet-Visible Spectroscopy. *Sustainability*. 13(14), 7907.

LAMPIRAN

Lampiran 1. Skema kerja penelitian



Lampiran 2. Kurva baku AmB dalam PBS + SLS 2%



Gambar 5. Kurva baku *amphotericin B* dalam PBS + SLS 2%

Lampiran 3. Perhitungan data

Lampiran 3.1 Uji pelepasan *in vitro*

$$\text{Persamaan: } y = 0,0296x + 0,0079$$

Keterangan:

x = konsentrasi

y = absorbansi

Untuk NE-AmB replikasi 1 jam ke-3 diperoleh absorbansi = 0,158 dengan faktor pengenceran = 4

$$y = 0,0296x + 0,0079$$

$$0,158 = 0,0296x + 0,0079$$

$$x = \frac{(0,158 - 0,0079)}{0,0296}$$

$$x = 5,07094$$

$$x = 5,07094 \mu\text{g/mL}$$

$$\text{Konsentrasi dalam 1 mL} = 5,07094 \mu\text{g/mL} \times 1 \text{ mL}$$

$$= 20,28376 \mu\text{g}$$

$$= 0,00507094 \text{ mg}$$

$$\text{Konsentrasi dalam 28 mL} = 0,00507094 \text{ mg} \times 28 \text{ mL} \times 4$$

$$= 0,56794 \text{ mg}$$

$$\text{Faktor koreksi} = \frac{\text{konsentrasi jam sebelumnya}}{1000} + \text{faktor koreksi jam sebelumnya}$$

$$= \frac{4,05743}{1000} + 0,003956$$

$$= 0,008007$$

$$\begin{aligned} \text{Jumlah pelepasan} &= \text{konsentrasi dalam 28 mL} + \text{faktor koreksi} \\ &= 0,56794 + 0,008007 \\ &= 0,57594 \text{ mg} \end{aligned}$$

$$\begin{aligned} \% \text{ pelepasan} &= \frac{\text{jumlah pelepasan}}{10} \times 100 \\ &= \frac{0,057594}{10} \times 100 \\ &= 5,760 \end{aligned}$$

Lampiran 3.2 Uji permeasi *ex vivo*

Keterangan:

x = konsentrasi

y = absorbansi

Untuk NE-TG-AmB replikasi 1 jam ke-7 diperoleh absorbansi = 0,686 dengan

faktor pengenceran = 8

$$y = 0,0296x + 0,0079$$

$$0,686 = 0,0296x + 0,0079$$

$$x = \frac{(0,686 - 0,0079)}{0,0296}$$

$$x = 22,90878$$

$$x = 22,90878 \mu\text{g/mL}$$

$$\text{Konsentrasi dalam 1 mL} = 22,90878 \mu\text{g/mL} \times 1 \text{ mL}$$

$$= 22,90878 \mu\text{g}$$

$$= 0,02290 \text{ mg}$$

$$\text{Konsentrasi dalam 28 mL} = 0,02290 \text{ mg} \times 28 \text{ mL} \times 8$$

$$= 5,13156 \text{ mg}$$

$$\text{Faktor koreksi} = \frac{\text{konsentrasi jam sebelumnya}}{1000} + \text{faktor koreksi jam sebelumnya}$$

$$= \frac{15,67905}{1000} + 0,02964$$

$$= 0,04532$$

$$\text{Jumlah terpermeasi} = \text{konsentrasi dalam 28 mL} + \text{faktor koreksi}$$

$$= 5,13156 + 0,04532$$

$$= 5,17689 \text{ mg}$$

$$\% \text{ permeasi} = \frac{\text{jumlah terpermeasi}}{10} \times 100$$

$$= \frac{5,17689}{10} \times 100$$

$$= 51,77$$

Lampiran 3.3 Uji retensi *ex vivo*

Persamaan: $y = 0,0293x + 0,0054$

Keterangan:

x = konsentrasi

y = absorbansi

Untuk NE-TG-AmB replikasi 1 jam ke-8 diperoleh absorbansi = 0,508

$y = 0,0293x + 0,0054$

$0,508 = 0,0293x + 0,0054$

$$x = \frac{(0,508 - 0,0054)}{0,0293}$$

$x = 17,15476 \mu\text{g/mL}$

Lampiran 4. Tabel hasil evaluasi
Tabel 3. Uji pelepasan *in vitro*

NE-AmB								
Waktu	Faktor pengenceran	Absorbansi	Konsentrasi ($\mu\text{g/mL}$)	28 mL (mg)	Faktor koreksi	Persen pelepasan (%)	Rata-rata (%)	SD
1	2	0,125	3,96	0,22	0,000	2,22	2,44	0,25
		0,137	4,36	0,24	0,000	2,44		
		0,149	4,77	0,27	0,000	2,67		
2	4	0,128	4,06	0,45	0,004	4,58	4,96	0,38
		0,138	4,40	0,49	0,004	4,97		
		0,148	4,73	0,53	0,005	5,35		
3	4	0,158	5,07	0,57	0,008	5,76	6,32	0,756
		0,173	5,58	0,62	0,009	6,33		
		0,187	6,05	0,68	0,010	6,87		
4	4	0,265	8,69	0,97	0,013	9,86	10,86	1,00
		0,291	9,56	1,07	0,014	10,86		
		0,317	10,44	1,17	0,016	11,85		
5	8	0,254	8,31	1,86	0,022	18,84	20,61	1,77
		0,277	9,09	2,04	0,024	20,60		
		0,300	9,87	2,21	0,026	22,37		
6	8	0,335	11,05	2,48	0,030	25,05	27,66	2,60
		0,369	12,20	2,73	0,033	27,66		
		0,403	13,35	2,99	0,036	30,26		

Waktu	Faktor pengenceran	Absorbansi	Konsentrasi ($\mu\text{g/mL}$)	28 mL (mg)	Faktor koreksi	Persen pelepasan (%)	Rata-rata (%)	SD
7	8	0,473	15,71	3,52	0,041	35,61	39,03	3,41
		0,518	17,23	3,86	0,045	39,05		
		0,562	18,72	4,19	0,049	42,42		
8	8	0,689	23,01	5,15	0,057	52,11	56,28	4,18
		0,743	24,83	5,56	0,062	56,25		
		0,798	26,69	5,98	0,068	60,47		
12	8	0,785	26,26	5,88	0,080	59,61	66,42	6,70
		0,877	29,36	6,58	0,087	66,64		
		0,960	32,17	7,21	0,095	73,00		
24	8	1,201	40,31	9,03	0,106	91,35	85,00	5,83
		1,099	36,86	8,26	0,117	83,74		
		1,047	35,10	7,86	0,127	79,90		

AmB Pure Drug

Waktu	Faktor pengenceran	Absorbansi	Konsentrasi (µg/mL)	28 mL (mg)	Faktor koreksi	Persen pelepasan (%)	Rata-rata (%)	SD
1	1	0,025	0,58	0,02	0,000	0,16	0,17	0,01
		0,026	0,61	0,02	0,000	0,17		
		0,028	0,68	0,02	0,000	0,19		
2	1	0,036	0,95	0,03	0,001	0,27	0,30	0,03
		0,038	1,02	0,03	0,001	0,29		
		0,042	1,15	0,03	0,001	0,33		
3	1	0,095	2,94	0,08	0,002	0,84	0,93	0,10
		0,103	3,21	0,09	0,002	0,92		
		0,115	3,62	0,10	0,002	1,03		
4	1	0,176	5,68	0,16	0,004	1,63	1,78	0,16
		0,187	6,05	0,17	0,005	1,74		
		0,209	6,79	0,19	0,005	1,96		
5	1	0,252	8,25	0,23	0,010	2,41	2,67	0,28
		0,275	9,02	0,25	0,011	2,64		
		0,309	10,17	0,28	0,012	2,97		
6	1	0,315	10,38	0,29	0,018	3,09	3,26	0,15
		0,339	11,19	0,31	0,020	3,33		
		0,340	11,22	0,31	0,022	3,37		

Waktu	Faktor pengenceran	Absorbansi	Konsentrasi ($\mu\text{g/mL}$)	28 mL (mg)	Faktor koreksi	Persen pelepasan (%)	Rata-rata (%)	SD
7	2	0,473	15,71	3,52	0,029	5,72	6,25	0,55
		0,518	17,23	3,86	0,031	6,22		
		0,562	18,72	4,19	0,034	6,81		
8	2	0,689	23,01	5,15	0,038	7,44	8,21	0,76
		0,743	24,83	5,56	0,042	8,23		
		0,798	26,69	5,98	0,045	8,97		
12	2	0,785	26,26	5,88	0,051	9,84	10,79	0,95
		0,877	29,36	6,58	0,056	10,79		
		0,960	32,17	7,21	0,060	11,75		
24	2	1,201	40,31	9,03	0,068	10,80	12,84	2,04
		1,099	36,86	8,26	0,074	12,83		
		1,047	35,10	7,86	0,080	14,88		

Tabel 4. Uji permeasi *ex vivo*

NE-TG-AmB								
Waktu	Faktor pengenceran	Absorbansi	Konsentrasi ($\mu\text{g/mL}$)	28 mL (mg)	Faktor koreksi	Persen permeasi (%)	Rata-rata (%)	SD
0,5	2	0,040	1,08	0,06	0,000	0,60	0,66	0,05
		0,043	1,19	0,07	0,000	0,66		
		0,045	1,25	0,07	0,000	0,70		
1	4	0,037	0,98	0,11	0,001	1,11	1,23	0,11
		0,040	1,08	0,12	0,001	1,23		
		0,043	1,19	0,13	0,001	1,34		
2	8	0,086	2,64	0,59	0,002	5,93	6,59	0,68
		0,094	2,91	0,65	0,002	6,54		
		0,104	3,25	0,73	0,002	7,30		
3	8	0,143	4,56	1,02	0,005	10,27	11,31	1,03
		0,157	5,04	1,13	0,005	11,34		
		0,170	5,48	1,23	0,006	12,33		
4	8	0,265	8,69	1,95	0,009	19,55	21,43	1,90
		0,289	9,50	2,13	0,010	21,37		
		0,315	10,38	2,32	0,011	23,35		
5	8	0,354	11,69	2,62	0,018	26,37	29,27	2,90
		0,392	12,98	2,91	0,020	29,26		
		0,430	14,26	3,20	0,022	32,17		

Waktu	Faktor pengenceran	Absorbansi	Konsentrasi (µg/mL)	28 mL (mg)	Faktor koreksi	Persen permeasi (%)	Rata-rata (%)	SD
6	8	0,472	15,68	3,51	0,030	35,42	39,33	3,93
		0,523	17,40	3,90	0,033	39,31		
		0,575	19,16	4,29	0,036	43,27		
7	8	0,686	22,91	5,13	0,045	51,77	57,27	5,50
		0,758	25,34	5,68	0,050	57,27		
		0,83	27,77	6,22	0,055	62,76		
8	12	0,559	18,62	6,26	0,068	63,24	69,44	6,20
		0,613	20,44	6,87	0,075	69,44		
		0,667	22,27	7,48	0,083	75,64		
12	12	0,780	26,08	8,76	0,087	88,51	97,87	9,34
		0,862	28,85	9,70	0,096	97,91		
		0,943	31,59	10,61	0,105	107,20		
24	16	0,892	29,87	13,38	0,113	134,94	144,35	8,32
		0,973	32,60	14,61	0,125	147,32		
		0,995	33,35	14,94	0,137	150,76		

TG-AmB

Waktu	Faktor pengenceran	Absorbansi	Konsentrasi ($\mu\text{g/mL}$)	28 mL (mg)	Faktor koreksi	Persen permeasi (%)	Rata-rata (%)	SD
0,5	2	0,017	0,31	0,02	0,000	0,17	0,19	0,02
		0,018	0,34	0,02	0,000	0,19		
		0,019	0,38	0,02	0,000	0,21		
1	4	0,020	0,41	0,05	0,000	0,46	0,50	0,04
		0,021	0,44	0,05	0,000	0,50		
		0,022	0,48	0,05	0,000	0,54		
2	4	0,089	2,74	0,31	0,001	3,08	3,33	0,25
		0,096	2,98	0,33	0,001	3,34		
		0,102	3,18	0,36	0,001	3,57		
3	4	0,131	4,16	0,47	0,003	4,69	5,11	1,42
		0,142	4,53	0,51	0,004	5,11		
		0,153	4,90	0,55	0,004	5,53		
4	8	0,103	3,21	0,72	0,008	7,27	12,69	0,73
		0,112	3,52	0,79	0,008	7,96		
		0,122	3,85	0,86	0,009	8,72		
5	8	0,157	5,04	1,13	0,011	11,39	18,69	1,30
		0,174	5,61	1,26	0,012	12,69		
		0,191	6,19	1,39	0,013	13,98		

Waktu	Faktor pengenceran	Absorbansi	Konsentrasi (µg/mL)	28 mL (mg)	Faktor koreksi	Persen permeasi (%)	Rata-rata (%)	SD
6	8	0,151	4,83	1,62	0,016	16,40	18,69	2,23
		0,254	8,31	1,86	0,017	18,80		
		0,281	9,23	2,07	0,019	20,86		
7	8	0,339	11,19	2,51	0,021	25,26	27,05	1,99
		0,357	11,79	2,64	0,026	26,68		
		0,39	12,91	2,89	0,028	29,20		
8	8	0,376	12,44	2,79	0,032	28,18	31,05	2,88
		0,413	13,69	3,07	0,038	31,03		
		0,451	14,97	3,35	0,041	33,94		
12	8	0,468	15,54	3,48	0,044	35,26	38,48	3,24
		0,509	16,93	3,79	0,051	38,43		
		0,552	18,38	4,12	0,056	41,74		
24	8	0,729	24,36	5,46	0,060	55,17	60,72	5,60
		0,800	26,76	5,99	0,068	60,62		
		0,875	29,29	6,56	0,074	66,36		

Tabel 5. Uji retensi *ex vivo*

NE-TG-AmB				
Waktu	Absorbansi	Konsentrasi ($\mu\text{g/mL}$)	Rata-rata (mg)	SD
0	0	0	0	0
	0	0		
	0	0		
1	0,611	20,655	21,068	3,735
	0,520	17,557		
	0,738	24,992		
2	0,905	30,717	31,331	5,555
	0,770	26,109		
	1,094	37,168		
3	1,035	35,141	35,844	6,355
	0,881	29,870		
	1,251	42,520		
4	1,234	41,917	42,755	7,580
	1,049	35,629		
	1,491	50,719		
5	1,382	46,985	47,925	8,496
	1,176	39,938		
	1,671	56,852		

Waktu	Absorbansi	Konsentrasi ($\mu\text{g/mL}$)	Rata-rata (mg)	SD
6	0,754	25,548	26,059	4,620
	0,642	21,716		
	0,911	30,913		
7	0,640	21,672	22,106	3,919
	0,545	18,421		
	0,774	26,223		
8	0,508	17,155	17,498	3,102
	0,433	14,582		
	0,614	20,757		
12	0,427	14,373	14,660	2,599
	0,363	12,217		
	0,515	17,391		
24	0,353	11,864	12,102	2,145
	0,301	10,085		
	0,426	14,356		

TG-AmB				
Waktu	Absorbansi	Konsentrasi ($\mu\text{g/mL}$)	Rata-rata (mg)	SD
0	0	0	0	0
	0	0		
	0	0		
1	0,545	18,407	18,775	3,329
	0,464	15,646		
	0,658	22,273		
2	0,765	25,933	26,452	4,689
	0,651	22,043		
	0,925	31,379		
3	0,928	31,492	32,122	5,695
	0,790	26,769		
	1,122	38,106		
4	1,133	38,496	39,266	6,961
	0,964	32,722		
	1,370	46,580		
5	0,807	27,346	27,893	4,945
	0,686	23,244		
	0,975	33,088		

Waktu	Absorbansi	Konsentrasi ($\mu\text{g/mL}$)	Rata-rata (mg)	SD
6	0,535	18,063	18,425	3,266
	0,455	15,354		
	0,646	21,857		
7	0,261	8,739	8,914	0,166
	0,223	7,428		
	0,315	10,574		
8	0,034	0,962	0,981	0,023
	0,029	0,817		
	0,039	1,164		
12	0,010	0,168	0,171	0,004
	0,010	0,142		
	0,011	0,202		
24	0,010	0,168	0,171	0,008
	0,010	0,142		
	0,011	0,202		

Lampiran 5. Data hasil uji analisis statistik

Lampiran 5.1 Uji pelepasan *in vitro*

Test for normal distribution		
Anderson-Darling test		
A2*	0.4204	0.4854
P value	0.2592	0.1731
Passed normality test (alpha=0.05)?	Yes	Yes
P value summary	ns	ns
D'Agostino & Pearson test		
K2	1.450	1.645
P value	0.4844	0.4394
Passed normality test (alpha=0.05)?	Yes	Yes
P value summary	ns	ns
Shapiro-Wilk test		
W	0.8982	0.8839
P value	0.2091	0.1445
Passed normality test (alpha=0.05)?	Yes	Yes
P value summary	ns	ns
Kolmogorov-Smirnov test		
KS distance	0.1677	0.2254
P value	>0.1000	>0.1000
Passed normality test (alpha=0.05)?	Yes	Yes
P value summary	ns	ns
Number of values	10	10

Table Analyzed	Data 6				
Two-way ANOVA	Ordinary				
Alpha	0.05				
Source of Variation	% of total variation	P value	P value summary	Significant?	
Interaction	23.20	<0.0001	****	Yes	
Row Factor	43.74	<0.0001	****	Yes	
Column Factor	32.33	<0.0001	****	Yes	
ANOVA table	SS	DF	MS	F (DFn, DFd)	P value
Interaction	7984	9	887.1	F (9, 40) = 141.5	P<0.0001
Row Factor	15052	9	1672	F (9, 40) = 266.8	P<0.0001
Column Factor	11127	1	11127	F (1, 40) = 1775	P<0.0001
Residual	250.7	40	6.268		
Difference between column means					
Mean of IN VITRO_NE-AmB	31.96				
Mean of IN VITRO_PURE DRUG-AmB	4.721				
Difference between means	27.24				
SE of difference	0.6464				
95% CI of difference	25.93 to 28.54				
Data summary					
Number of columns (Column Factor)	2				

Šidák's multiple comparisons test	Mean Diff.	95.00% CI of diff.	Below threshold?	Summary	Adjusted P Value
IN VITRO_NE-AmB - IN VITRO_PURE DRUG-AmB					
1	2.269	-3.787 to 8.325	No	ns	0.9592
2	4.670	-1.386 to 10.73	No	ns	0.2452
3	5.392	-0.6636 to 11.45	No	ns	0.1122
4	9.078	3.022 to 15.13	Yes	***	0.0007
5	17.93	11.88 to 23.99	Yes	****	<0.0001
6	24.39	18.34 to 30.45	Yes	****	<0.0001
7	32.78	26.72 to 38.83	Yes	****	<0.0001
8	48.07	42.01 to 54.12	Yes	****	<0.0001
12	55.63	49.57 to 61.68	Yes	****	<0.0001
24	72.16	66.10 to 78.22	Yes	****	<0.0001

Lampiran 5.2 Uji permeasi *ex vivo*

Test for normal distribution		
Anderson-Darling test		
A2*	0.5233	0.4731
P value	0.1405	0.1925
Passed normality test (alpha=0.05)?	Yes	Yes
P value summary	ns	ns
D'Agostino & Pearson test		
K2	4.383	3.721
P value	0.1117	0.1556
Passed normality test (alpha=0.05)?	Yes	Yes
P value summary	ns	ns
Shapiro-Wilk test		
W	0.8738	0.8851
P value	0.0868	0.1208
Passed normality test (alpha=0.05)?	Yes	Yes
P value summary	ns	ns
Kolmogorov-Smirnov test		
KS distance	0.1731	0.1695
P value	>0.1000	>0.1000
Passed normality test (alpha=0.05)?	Yes	Yes
P value summary	ns	ns
Number of values	11	11

Table Analyzed	EX VIVO PER				
Two-way ANOVA	Ordinary				
Alpha	0.05				
Source of Variation	% of total variation	P value	P value summary	Significant?	
Interaction	12.65	<0.0001	****	Yes	
Row Factor	74.48	<0.0001	****	Yes	
Column Factor	12.12	<0.0001	****	Yes	
ANOVA table	SS	DF	MS	F (DFn, DFd)	P value
Interaction	10800	10	1080	F (10, 44) = 73.87	P<0.0001
Row Factor	62422	10	6242	F (10, 44) = 435.0	P<0.0001
Column Factor	10159	1	10159	F (1, 44) = 707.9	P<0.0001
Residual	631.4	44	14.35		
Difference between column means					
Mean of NE-TG-AmB	43.52				
Mean of TG-AmB	18.71				
Difference between means	24.81				
SE of difference	0.9326				
95% CI of difference	22.93 to 26.69				
Data summary					
Number of columns (Column Factor)	2				
Number of rows (Row Factor)	11				
Number of values	66				

Šidák's multiple comparisons test	Mean Diff.	95.00% CI of diff.	Below threshold?	Summary	Adjusted P Value
NE-TG-AmB - TG-AmB					
0,5	0.4623	-8.762 to 9.686	No	ns	>0.9999
1	0.7263	-8.498 to 9.950	No	ns	>0.9999
2	3.261	-5.963 to 12.49	No	ns	0.9794
3	6.202	-3.022 to 15.43	No	ns	0.4386
4	13.44	4.213 to 22.66	Yes	***	0.0009
5	16.58	7.355 to 25.80	Yes	****	<0.0001
6	20.65	11.42 to 29.87	Yes	****	<0.0001
7	30.22	21.00 to 39.44	Yes	****	<0.0001
8	38.39	29.17 to 47.61	Yes	****	<0.0001
12	59.40	50.17 to 68.62	Yes	****	<0.0001
24	83.62	74.40 to 92.85	Yes	****	<0.0001

Lampiran 5.3 Uji retensi ex vivo

Test for normal distribution		
Anderson-Darling test		
A2*	0.2473	0.3480
P value	0.6729	0.3994
Passed normality test (alpha=0.05)?	Yes	Yes
P value summary	ns	ns
D'Agostino & Pearson test		
K2	1.011	1.657
P value	0.6033	0.4368
Passed normality test (alpha=0.05)?	Yes	Yes
P value summary	ns	ns
Shapiro-Wilk test		
W	0.9448	0.9155
P value	0.6074	0.3212
Passed normality test (alpha=0.05)?	Yes	Yes
P value summary	ns	ns
Kolmogorov-Smirnov test		
KS distance	0.1618	0.1743
P value	>0.1000	>0.1000
Passed normality test (alpha=0.05)?	Yes	Yes
P value summary	ns	ns
Number of values	10	10

Table Analyzed	Data 1				
Two-way ANOVA	Ordinary				
Alpha	0.05				
Source of Variation	% of total variation	P value	P value summary	Significant?	
Interaction	4.489	0.0133	*	Yes	
Row Factor	75.89	<0.0001	****	Yes	
Column Factor	12.37	<0.0001	****	Yes	
ANOVA table	SS	DF	MS	F (DFn, DFd)	P value
Interaction	524.8	9	58.32	F (9, 40) = 2.750	P=0.0133
Row Factor	8873	9	985.8	F (9, 40) = 46.49	P<0.0001
Column Factor	1446	1	1446	F (1, 40) = 68.18	P<0.0001
Residual	848.2	40	21.21		
Difference between column means					
Mean of NE-TG-AmB	27.13				
Mean of TG-AmB	17.32				
Difference between means	9.818				
SE of difference	1.189				
95% CI of difference	7.415 to 12.22				
Data summary					
Number of columns (Column Factor)	2				
Number of rows (Row Factor)	10				
Number of values	60				

Šidák's multiple comparisons test	Mean Diff.	95.00% CI of diff.	Below threshold?	Summary	Adjusted P Value
NE-TG-AmB - TG-AmB					
1	2.293	-8.846 to 13.43	No	ns	0.9996
2	4.880	-6.259 to 16.02	No	ns	0.8950
3	3.721	-7.417 to 14.86	No	ns	0.9813
4	3.489	-7.650 to 14.63	No	ns	0.9883
5	20.03	8.894 to 31.17	Yes	****	<0.0001
6	7.634	-3.504 to 18.77	No	ns	0.3949
7	13.19	2.053 to 24.33	Yes	*	0.0112
8	16.52	5.378 to 27.66	Yes	***	0.0008
12	14.49	3.351 to 25.63	Yes	**	0.0041
24	11.93	0.7922 to 23.07	Yes	*	0.0286

Lampiran 6. Hasil uji kinetika secara *in vitro* menggunakan *add-ins* Microsoft Excel (DDsolver)

Time (h)	No.1 F(%)	Mean	SD	RSD(%)
0	000	000		
1	002	002		
2	005	005		
3	006	006		
4	011	011		
5	021	021		
6	028	028		
7	039	039		
8	056	056		
12	066	066		
24	085	085		

Best-fit Values

Parameter	No.1	Mean	SD	RSD(%)
kHC	0.000	0.000		

Secondary Parameter

Parameter	No.1	Mean	SD	RSD(%)
T25	0.004	0.004		
T50	0.010	0.010		
T75	0.018	0.018		
T80	0.020	0.020		
T90	0.026	0.026		

Goodness of Fit

Parameter	No.1
N_observed	11
DF	10
R_obs-pre	00.001
Rsqr	0,91652
Rsqr_adj	00.001
MSE	00.071
MSE_root	00.008
Weighting	1
SS	00.706
WSS	00.706
AIC	00.074
MSC	00.002

Lampiran 7. Hasil uji permeasi secara *ex vivo* menggunakan *add-ins* Microsoft Excel (DDsolver)


Time (h)	No.1 F(%)	Mean	SD	RSD(%)
0,5	001	001		
1	001	001		
2	007	007		
3	011	011		
4	021	021		
5	029	029		
6	039	039		
7	057	057		
8	069	069		
12	098	098		
24	144	144		

Best-fit Values				
Parameter	No.1	Mean	SD	RSD(%)
k0	0.007	0.007		

Secondary Parameter				
Parameter	No.1	Mean	SD	RSD(%)
T25	0.004	0.004		
T50	0.007	0.007		
T75	0.011	0.011		
T80	0.012	0.012		
T90	0.013	0.013		

Goodness of Fit	
Parameter	No.1
N_observed	11
DF	10
R_obs-pre	00.001
Rsqr	0,95052
Rsqr_adj	00.001
MSE	00.105
MSE_root	00.010
Weighting	1
SS	01.054
WSS	01.054
AIC	00.079
MSC	00.003

Lampiran 8. Dokumentasi



Gambar 6. Preparasi NE-AmB



Gambar 7. Preparasi NE-TG-AmB



Gambar 8. Uji pelepasan *In Vitro*



Gambar 9. Uji permeasi *Ex Vivo*



Gambar 10. Uji retensi *Ex Vivo*



Gambar 11. Penggunaan Spektrofotometer UV-Vis